Skip to main content
Search
Main content
Research square
Published

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

Authors

Stephanie Debette, Ilana Caro, Daniel Western, Shinichi Namba, Na Sun, Shuji Kawaguchi, Yunye He, Masashi Fujita, Gennady Roshchupkin, Tim D'Aoust, Marie-Gabrielle Duperron, Murali Sargurupremraj, Ami Tsuchida, Masaru Koido, Marziehsadat Ahmadi, Chengran Yang, Jigyasha Timsina, Laura Ibanez, Koichi Matsuda, Yutaka Suzuki, Yoshiya Oda, Akinori Kanai, Pouria Jandaghi, Hans Markus Munter, Dan Auld, Iana Astafeva, Raquel Puerta, Jerome Rotter, Bruce Psaty, Joshua Bis, Will Longstreth, Thierry Couffinhal, Pablo Garcia-Gonzalez, Vanesa Pytel, Marta Marquié, Amanda Cano, Mercè Boada, Marc Joliot, Mark Lathrop, Quentin Le Grand, Lenore Launer, Joanna Wardlaw, Myriam Heiman, Agustin Ruiz, Paul Matthews, Sudha Seshadri, Myriam Fornage, Hieab Adams, Aniket Mishra, David-Alexandre Trégouët, Yukinori Okada, Manolis Kellis, Philip De Jager, Christophe Tzourio, Yoichiro Kamatani, Fumihiko Matsuda, Carlos Cruchaga

Abstract

Res Sq [Preprint]. 2024 Jul 2:rs.3.rs-4535534. doi: 10.21203/rs.3.rs-4535534/v1.

ABSTRACT

Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia with no specific mechanism-based treatment. We used Mendelian randomization to combine a unique cerebrospinal fluid (CSF) and plasma pQTL resource with the latest European-ancestry GWAS of MRI-markers of cSVD (white matter hyperintensities, perivascular spaces). We describe a new biological fingerprint of 49 protein-cSVD associations, predominantly in the CSF. We implemented a multipronged follow-up, across fluids, platforms, and ancestries (Europeans and East-Asian), including testing associations of direct plasma protein measurements with MRI-cSVD. We highlight 16 proteins robustly associated in both CSF and plasma, with 24/4 proteins identified in CSF/plasma only. cSVD-proteins were enriched in extracellular matrix and immune response pathways, and in genes enriched in microglia and specific microglial states (integration with single-nucleus RNA sequencing). Immune-related proteins were associated with MRI-cSVD already at age twenty. Half of cSVD-proteins were associated with stroke, dementia, or both, and seven cSVD-proteins are targets for known drugs (used for other indications in directions compatible with beneficial therapeutic effects. This first cSVD proteogenomic signature opens new avenues for biomarker and therapeutic developments.

PMID:39011113 | PMC:PMC11247936 | DOI:10.21203/rs.3.rs-4535534/v1

UK DRI Authors

Joanna Wardlaw

Prof Joanna Wardlaw

Group Leader and Clinical Director of the CVDR

Discovering how small vessel disease damages the brain and what we can do to prevent or treat it

Prof Joanna Wardlaw
Paul Matthews

Prof Paul Matthews

Group Leader

Exploring neuronal vulnerability and genetic risk variants in Alzheimer’s progression

Prof Paul Matthews